Barbara Burtness, MD, FASCO - Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.